Literature DB >> 24327288

[Coping with wet age-related macular degeneration--a study from Switzerland].

S Hüsler1, H Schmid.   

Abstract

BACKGROUND: Age-related macular degeneration (AMD) affects the quality of life of about 40,000 patients in Switzerland. The treatment of wet AMD with intravitreal injected anti-vascular endothelial growth factor (VEGF) can be a heavy burden for many patients. The aim of this study was to understand the quality of life of the patients and to seek ways to improve the treatment compliance.
METHODS: Half-structured telephone interviews with 28 patients between 56 and 94 years of age were transcribed and analysed. In 21 patients, both eyes were concerned with AMD.
RESULTS: The quality of life of patients with AMD is reduced. Many activities of daily living are hindered. Dependence on others increases. Communication of the diagnosis is perceived as a shock. Most interviewees wish for more information about their specific situation. Auxiliary means and counselling possibilities are hardly known.
CONCLUSION: Wet AMD impacts on the quality of life of the patient. Treatment should therefore not be limited to the medical treatment of the ill eye. Triage to rehabilitation and counselling services should be included as important duties of the medical practitioners. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24327288     DOI: 10.1055/s-0033-1351029

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  4 in total

1.  Emotional and physical experiences of people with neovascular age-related macular degeneration during the injection process in Germany: a qualitative study.

Authors:  Anne Thier; Martina Breuning; Christian Wolfram; Oliver Zeitz; Christine Holmberg
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

2.  [Internet search for counseling offers for older adults suffering from visual impairment].

Authors:  I Himmelsbach; J Lipinski; M Putzke
Journal:  Ophthalmologe       Date:  2016-11       Impact factor: 1.059

3.  Treatment of age-related neovascular macular degeneration: the patient's perspective.

Authors:  S Müller; C Ehlken; U Bauer-Steinhusen; W Lechtenfeld; Z Hasanbasic; H Agostini; T Wilke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-04       Impact factor: 3.117

4.  How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview.

Authors:  Theodoros Empeslidis; Matthew Storey; Theodoros Giannopoulos; Vassileios Konidaris; Paris G Tranos; Evangelia S Panagiotou; Irini C Voudouragkaki; Anastasios G Konstas
Journal:  Adv Ther       Date:  2019-05-17       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.